Chronic Obstructive Pulmonary Disease ( Copd )

1921 WordsAug 27, 20148 Pages
Chronic Obstructive Pulmonary Disease (COPD) is progressively common amongst patients within the United States. The disease is more common in patients with a long smoking history. Inflammatory changes are largely responsible for the development and symptoms of COPD. COPD is typically managed according to classification of severity based on the GOLD guidelines. Anoro Ellipta is a new once daily FDA approved drug. It is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting b2-agonist that should be considered in the management of COPD. Efficacy studies have proved Anoro Eliipta in preventing COPD exacerbations and show it is well tolerated amongst patients. Learning Objectives • Define COPD and identify risk factors • Understand the inflammatory changes in COPD • Understand basic principles of COPD therapy Key Words: COPD, spirometery, bronchodilator, inflammation, elastase, GOLD criteria, inhaler Clinical Scenario An overweight 62-year-old male patient with a 30-pack year history presents to your private office. He is complaining of progressively worsening breathlessness over the last two years. He has also noted excess mucus and sputum production for about three months for each of those years. On physical exam wheezing is present on auscultation. Spirometry shows a decreased FEV1/FVC to 65% of the expected range. The diagnosis of chronic bronchitis is made. What is the best way to manage this patient? According to the WHO, to effectively manage
Open Document